Turn Therapeutics Inc. updates investor presentation.
- Released an updated investor presentation on October 6, 2026.
- Phase 2 trial for moderate to severe AD topline results expected Q1 2027.
- Phase 3 initiation for onychomycosis planned for mid-2027.
Every EDGAR filing for Turn Therapeutics Inc. (TTRX), newest first, with AI summaries and stories.
Next: earnings expected ~Nov 12 · 10-Q expected ~Nov 12 (deadline Nov 16)
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Martin William Dewhurst, insider filing for TTRX
Martin William Dewhurst, reporting
BEB Holdings, LLC, insider filing for TTRX
BEB Holdings, LLC, reporting · Bradley Evan Burnam, reporting
Ownership stake disclosure by Bradley Evan Burnam
Bradley Evan Burnam, filed by
BEB Holdings, LLC, insider filing for TTRX
BEB Holdings, LLC, reporting · Bradley Evan Burnam, reporting
Martin William Dewhurst, insider filing for TTRX
Martin William Dewhurst, reporting
Zuraiz Chaudhary, insider filing for TTRX
Zuraiz Chaudhary, reporting
Arthur F Golden, insider filing for TTRX
Arthur F Golden, reporting
Zuraiz Chaudhary, reporting